Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.
|Articles|November 26, 2012
FDA panel votes against OTC use of OAB agent
An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.
Advertisement
Advertisement
Related to this article
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
2
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
3
Trutakna Reduces Proteinuria in Adults With Primary IgAN
4
Pharmacists Step Up on Test-To-Treat This American Pharmacist Month
5